Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.
--------
Question: Five or six years ago, I attended a lecture on the science of attention. A professor who conducts research over in the medical school was talking about attention blindness, the basic feature of the human brain that, when we concentrate on one task, causes us to miss just about everything else. Because we can't see what we can't see, our lecturer was determined to catch us in the act. He had us watch a video of six people tossing basketballs back and forth, three in white shirts and three in black, and our task was to keep track only of the tosses among the people in white. The tape rolled, and everyone began counting. Everyone except me. I'm dyslexic , and the moment I saw that tape with the confusing basketball tossers, I knew I wouldn't be able to keep track of their movements, so I let my mind wander. I became curious, though, when about 30 seconds into the tape, a gorilla walked in among the players. She (we later learned a female student was in the gorilla suit) stared at the camera, beat her chest with her fist, and then went away while they continued passing the balls. When the tape stopped, the professor asked how many people had counted at least a dozen basketball tosses. Hands went up all over. He then asked who had counted 13, 14, and congratulated those who'd scored the perfect 15. Then he asked, "And who saw the gorilla?" I raised my hand and was surprised to discover I was the only person at my table and one of only three or four in the large room to do so. He'd set us up, trapping us in our own attention blindness. Yes, there had been a trick, but he wasn't the one who had played it on us. By concentrating so hard on counting, we had managed to miss the gorilla in the midst. Attention blindness is the fundamental organizing principle of the brain, and I believe that it presents us with a great opportunity. My take is different from that of many neuroscientists: Where they see the shortcomings of the individual, I sense an opportunity for cooperation. Fortunately, given the interactive nature of most of our lives in the digital age, we have the tools to control our different forms of attention and take advantage of them. It's not easy to admit that everything we've learned about how to pay attention means that we've been missing everything else. It's not easy for us logical, intelligent, confident types to admit that the very key to our success -- our ability to discover a problem and solve it, an achievement obtained in all those years in school and beyond -- may be exactly what limits us. No one ever told us that our way of seeing left out everything else.

Answer: What's the total number of basketball tosses by the players in white shirts in the video?

Question: Protein kinases (PKs) and lipid kinases (LKs) are good choices for targets of signal transduction therapy as these enzymes are involved in signaling pathways, and are often related to the pathogenesis of lymphoid malignancies. The attractiveness of PKs and LKs as drug able targets is enhanced by the fact that they are enzymes whose biological activity can be turned off by drugs that block their catalytic site. In the last few years small molecular kinase inhibitors (KIs) have been synthesized and become available for preclinical studies and clinical trials. The first KI, introduced into clinical practice in 1998, was imatinib mesylate, which became the first choice drug in chronic myeloid leukemia. More recently, several KIs have been developed to target the proximal B-cell receptor (BCR) signaling pathway including spleen tyrosine kinase inhibitor (Fostamatinib) and Bruton's tyrosine kinase inhibitors (Ibrutinib, AVL-263). These agents are currently evaluated in early clinical trials in chronic lymphocytic leukemia (CLL) and other diseases. Cyclin-dependent kinase (Cdk) inhibitors, flavopiridol (alvocidib), BMS-387032 (SNS-032), sunitinib and sorafenib are currently under evaluation in clinical trials for relapsed/refractory CLL. Multi-tyrosine kinase inhibitors including vandetanib (ZD6474) bosutinib (SKI-606), TKI258 (CHIR-258), pazopanib (GW786034) and axitinib (AG013736) have been also developed for the treatment of lymphoid malignancies. Phosphatidylinositol 3-kinases (PI3K ) are a family of lipid kinases that mediate signals from cell surface receptors. CAL-101 (GS-1101) is an oral PI3K-specific inhibitor which has shown preclinical and clinical activity against CLL. This article summarizes recent achievements in the mechanism of action, pharmacological properties and clinical activity and toxicity of PK and LK inhibitors in CLL.

Answer: What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?

Question: The Battle of al-Qadisiyyah (Arabic: ; transliteration, Ma'rakatu al-Qadisiyyah; Persian: transliteration Nabard-e Qadesiyeh; alternative spellings: Qadisiyya, Qadisiyyah, Kadisiya, Ghadesiyeh), fought in 636, is said to be a decisive engagement between the Arab Muslim army and the Sassanid Persian army during the first period of Muslim expansion.

Answer:
On what date did Battle of al-Qadisiyyah end?